FDA Recalls Testosterone/Anastrozole Pellets Due to Sterility Concerns
JD & SN Inc. is recalling Testosterone/Anastrozole pellets because the FDA identified a lack of assurance of sterility for the compounded drugs.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The source text explicitly identifies the recall as FDA Class II. According to the severity rubric, an FDA Class II recall is classified as Severe (Score 4), particularly when involving sterile compounded drugs where sterility assurance is compromised.
Plain-English summary
The U.S. Food and Drug Administration (FDA) has issued a Class II recall for Testosterone/Anastrozole, Pellet, 120/8 mg, manufactured by JD & SN Inc., dba Moses Lake Professional Pharmacy. The recall was initiated due to a lack of assurance of sterility for all sterile human compounded drugs within their expiry dates.
The affected product consists of 20 pellets per unit. The specific lot codes involved are t05132014@15, t08262014@18, and t11112014@21. The distribution pattern for these products is listed as nationwide.
Patients who have received these specific compounded pellets should contact their healthcare provider or pharmacist for guidance on next steps. The FDA classifies this as a Class II recall, indicating that use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- TESTOSTERONE/ANASTROZOLE, Pellet, 120/8 mg, Rx only, JD & SN Inc, DBA Moses Lake Professional Pharmacy, 1555 S. Pilgrim St. Moses Lake WA 98837, (509)764-2314
- Category
- Drug — Compounded Sterile Drug
- Affected units
- 20
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- t05132014@15
- t08262014@18
- t11112014@21.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 101 recalled by JD & SN Inc., dba Moses Lake Professional Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 101 products in this recall →Related recalls
Same manufacturer · JD & SN Inc., dba Moses Lake Professional Pharmacy
See all →- SevereFDA Recalls Estradiol Pellets Due to Lack of Sterility Assurance
FDA (Drugs) · 2015-11-04
- SevereFDA Recalls Sodium Tetradecyl Sulfate Syringes Due to Sterility Concerns
FDA (Drugs) · 2015-11-04
- SevereMoses Lake Pharmacy Recalls Six Trimix Syringes Due to Sterility Concerns
FDA (Drugs) · 2015-11-04
- SevereMoses Lake Pharmacy Recalls Compounded Chorionic Gonadotropin Due to Sterility Concerns
FDA (Drugs) · 2015-11-04
- SevereFDA Recalls Compounded Progesterone Pellets Due to Sterility Concerns
FDA (Drugs) · 2015-11-04
Same hazard · sterility
See all →- HighFDA recalls injectable compounded mixture in single-use syringes
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereFDA Recalls Testosterone and Anastrazole Pellets Due to Sterility Concerns
FDA (Drugs) · 2015-09-23
- SevereTestosterone and Anastrazole Pellets Recalled for Sterility Concerns
FDA (Drugs) · 2015-09-23
- SevereFDA Recalls Wells Pharmacy Testosterone and Anastrozole Pellets
FDA (Drugs) · 2016-11-16
- SeverePartell Specialty Pharmacy Recalls Testosterone Pellets Due to Sterility Concerns
FDA (Drugs) · 2018-04-25
- SeverePartell Specialty Pharmacy Recalls Testosterone and Anastrozole Pellets for Sterility Concerns
FDA (Drugs) · 2018-04-25
- SeverePartell Specialty Pharmacy Recalls Testosterone/Anastrozole Pellets Due to Sterility Concerns
FDA (Drugs) · 2018-04-25